

Sierra Leone

Support for Vaccine: Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Sierra Leone

2. **Vaccine grant number:** SLE-HPV-R

3. **Date of Decision Letter:** 22 February 2022

4. **Date of the Partnership Framework Agreement:** 31 October 2013

5. **Programme title:** New Vaccine Support (NVS), Human Papillomavirus Vaccine (HPV), Routine

6. **Vaccine type:** Human Papillomavirus Vaccine (HPV)

7. **Requested product presentation and formulation of vaccine:**

HPV4, 1 dose/vial, liquid

8. **Programme duration:**¹ 2019-2022

9. **Programme Budget (indicative):**²³ (subject to the terms of the Partnership Framework Agreement, if applicable)

	2019-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget(US\$)	17.738	906.256	1.333.124	-	-	-	2.257.118

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2019	SLE-HPV-R-VIG	255.322

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³ This is the amount that Gavi has approved.

11. Product switch grant:

Not applicable

Type of supplies to be purchased with Gavi funds	2019-2020	2021	2022
Number of vaccine doses	-	193.900	288.500
Number of AD syringes	-	227.100	301.800
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	2.500	3.325
Annual Amounts (US\$)	17.738	906.256	1.333.124

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:	Initial self-financing				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2021	2022	2023	2024	2025
Number of vaccine doses	10.000	13.200	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	45.000	59.400	-	-	-
Total co-financing payments (US\$) (including freight)	45.476	60.370	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none">• vaccine stock levels including buffer stock, by end of March;• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.• Countries shall report the actual switch date in the first renewal request following the actual implementation.	31 March 15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

For the Gavi Alliance



By:

Name: Colette Selman

Title: Director a.i. Core Countries

Date: 22 February 2022